Lupin gets tentative US FDA approval for Apixaban suspension
In short
Lupin said it got tentative approval from the U.S. FDA for its Apixaban oral suspension application. The report names the drug and the regulator, but not a launch date.
This could help Lupin move toward the U.S. market. The story did not say whether final approval is still needed or when sales might start.
What the reporting says
Lupin said it received tentative approval from the U.S. FDA for its new drug application for Apixaban oral suspension, according to the Business Standard summary. The report identifies the drug and the regulator but does not state the approval’s commercial timing or whether full approval is still pending. The immediate significance is potential U.S. market access, though the final launch status was not stated.
Why it matters
Lupin’s tentative FDA approval for Apixaban oral suspension is a regulatory step that may support future U.S. sales if final clearance follows. The announcement is relevant to Lupin’s pharmaceuticals business and to investors watching generic or specialty drug approvals. The reporting does not state the product’s target market timing, expected revenue, or whether any additional approvals remain.